{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:07:33Z","timestamp":1792786053360,"version":"4.5.0"},"reference-count":26,"publisher":"Oxford University Press (OUP)","issue":"10","license":[{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"name":"Department of Defense Neurofibromatosis Research Program","award":["W81XWH"],"award-info":[{"award-number":["W81XWH"]}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P50CA165962"],"award-info":[{"award-number":["P50CA165962"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,10,14]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Activation of the mammalian target of rapamycin (mTOR) pathway is observed in neurofibromatosis type 1 (NF1) associated low-grade gliomas (LGGs), but agents that inhibit this pathway, including mTOR inhibitors, have not been studied in this population. We evaluate the efficacy of the orally administered mTOR inhibitor everolimus for radiographically progressive NF1-associated pediatric LGGs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Children with radiologic-progressive, NF1-associated LGG and prior treatment with a carboplatin-containing chemotherapy were prospectively enrolled on this phase II clinical trial to receive daily everolimus. Whole blood was analyzed for everolimus and markers of phosphatidylinositol-3 kinase (PI3K)\/mTOR pathway inhibition. Serial MRIs were obtained during treatment. The primary endpoint was progression-free survival at 48 weeks.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Twenty-three participants (median age, 9.4 y; range, 3.2\u201321.6 y) were enrolled. All participants were initially evaluable for response; 1 patient was removed from study after development of a malignant peripheral nerve sheath tumor. Fifteen of 22 participants (68%) demonstrated a response, defined as either shrinkage (1 complete response, 2 partial response) or arrest of tumor growth (12 stable disease). Of these, 10\/15 remained free of progression (median follow-up, 33 mo). All remaining 22 participants were alive at completion of therapy. Treatment was well tolerated; no patient discontinued therapy due to toxicity. Pharmacokinetic parameters and pre-dose concentrations showed substantial between-subject variability. PI3K\/mTOR pathway inhibition markers demonstrating blood mononuclear cell mTOR pathway inactivation was achieved in most participants.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Individuals with recurrent\/progressive NF1-associated LGG demonstrate significant disease stability\/shrinkage during treatment with oral everolimus with a well-tolerated toxicity profile. Everolimus is well suited for future consideration as upfront or combination therapy in this patient population.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/neuonc\/noaa071","type":"journal-article","created":{"date-parts":[[2020,3,31]],"date-time":"2020-03-31T15:21:10Z","timestamp":1585668070000},"page":"1527-1535","source":"Crossref","is-referenced-by-count":87,"title":["A phase II study of continuous oral mTOR inhibitor everolimus for recurrent, radiographic-progressive neurofibromatosis type 1\u2013associated pediatric low-grade glioma: a Neurofibromatosis Clinical Trials Consortium study"],"prefix":"10.1093","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5623-3362","authenticated-orcid":false,"given":"Nicole J","family":"Ullrich","sequence":"first","affiliation":[{"name":"Department of Neurology, Boston Children\u2019s Hospital, Boston, Massachusetts"},{"name":"Dana-Farber\/Boston Children\u2019s Cancer and Blood Disorders, Dana-Farber Cancer Institution, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjay P","family":"Prabhu","sequence":"additional","affiliation":[{"name":"Departments of Radiology, Boston Children\u2019s Hospital, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alyssa T","family":"Reddy","sequence":"additional","affiliation":[{"name":"Department of Neurology, School of Medicine, University of California San Francisco, San Francisco, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J","family":"Fisher","sequence":"additional","affiliation":[{"name":"Division of Oncology, Children\u2019s Hospital of Philadelphia, Philadelphia, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger","family":"Packer","sequence":"additional","affiliation":[{"name":"Center for Neuroscience and Behavioral Medicine, Children\u2019s National Health System, Washington, DC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stewart","family":"Goldman","sequence":"additional","affiliation":[{"name":"Ann and Robert Lurie Children\u2019s Hospital, Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathan J","family":"Robison","sequence":"additional","affiliation":[{"name":"Children\u2019s Center for Cancer and Blood Diseases, Children\u2019s Hospital Los Angeles, University of Southern California Keck School of Medicine, Los Angeles, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David H","family":"Gutmann","sequence":"additional","affiliation":[{"name":"Department of Neurology, Washington University School of Medicine, St Louis, Missouri"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David H","family":"Viskochil","sequence":"additional","affiliation":[{"name":"Department of Genetics, University of Utah, Salt Lake City, Utah"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey C","family":"Allen","sequence":"additional","affiliation":[{"name":"Departments of Pediatrics and Neurology, NYU Cancer Institute, NYU Langone Medical Center, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruce","family":"Korf","sequence":"additional","affiliation":[{"name":"Department of Genetics, University of Utah, Salt Lake City, Utah"},{"name":"Department of Medical Genetics, University of Alabama, Birmingham, Alabama"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan","family":"Cantor","sequence":"additional","affiliation":[{"name":"Department of Preventative Medicine, University of Alabama, Birmingham, Alabama"},{"name":"Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary","family":"Cutter","sequence":"additional","affiliation":[{"name":"School of Public Health, University of Alabama, Birmingham, Alabama"},{"name":"Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Coretta","family":"Thomas","sequence":"additional","affiliation":[{"name":"School of Public Health, University of Alabama, Birmingham, Alabama"},{"name":"Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John P","family":"Perentesis","sequence":"additional","affiliation":[{"name":"Division of Oncology, Cincinnati Children\u2019s Hospital Medical Center, Cincinnati, Ohio"},{"name":"Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoyuki","family":"Mizuno","sequence":"additional","affiliation":[{"name":"Division of Clinical Pharmacology, Cincinnati Children\u2019s Hospital Medical Center, Cincinnati, Ohio"},{"name":"Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander A","family":"Vinks","sequence":"additional","affiliation":[{"name":"Division of Clinical Pharmacology, Cincinnati Children\u2019s Hospital Medical Center, Cincinnati, Ohio"},{"name":"Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter E","family":"Manley","sequence":"additional","affiliation":[{"name":"Department of Hematology\/Oncology, Boston Children\u2019s Hospital, Boston, Massachusetts"},{"name":"Dana-Farber\/Boston Children\u2019s Cancer and Blood Disorders, Dana-Farber Cancer Institution, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan N","family":"Chi","sequence":"additional","affiliation":[{"name":"Department of Hematology\/Oncology, Boston Children\u2019s Hospital, Boston, Massachusetts"},{"name":"Dana-Farber\/Boston Children\u2019s Cancer and Blood Disorders, Dana-Farber Cancer Institution, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark W","family":"Kieran","sequence":"additional","affiliation":[{"name":"Department of Hematology\/Oncology, Boston Children\u2019s Hospital, Boston, Massachusetts"},{"name":"Dana-Farber\/Boston Children\u2019s Cancer and Blood Disorders, Dana-Farber Cancer Institution, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2020,4,1]]},"reference":[{"issue":"4","key":"2020101413244156400_CIT0001","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1016\/j.ncl.2007.07.008","article-title":"Genetic causes of brain tumors: neurofibromatosis, tuberous sclerosis, von Hippel-Lindau, and other syndromes","volume":"25","author":"Farrell","year":"2007","journal-title":"Neurol Clin."},{"issue":"4","key":"2020101413244156400_CIT0002","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1227\/01.NEU.0000298904.63635.2D","article-title":"Brainstem lesions in neurofibromatosis type 1","volume":"61","author":"Ullrich","year":"2007","journal-title":"Neurosurgery"},{"issue":"16","key":"2020101413244156400_CIT0003","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1212\/WNL.0000000000003881","article-title":"A multi-institutional study of brainstem gliomas in children with neurofibromatosis type 1","volume":"88","author":"Mahdi","year":"2017","journal-title":"Neurology."},{"issue":"21","key":"2020101413244156400_CIT0004","doi-asserted-by":"crossref","first-page":"2641","DOI":"10.1200\/JCO.2011.36.6054","article-title":"Randomized study of two chemotherapy regimens for treatment of low-grade glioma in young children: a report from the Children\u2019s Oncology Group","volume":"30","author":"Ater","year":"2012","journal-title":"J Clin Oncol."},{"issue":"2","key":"2020101413244156400_CIT0005","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1007\/s11060-010-0159-z","article-title":"Natural history and management of low-grade glioma in NF-1 children","volume":"100","author":"Hern\u00e1iz Driever","year":"2010","journal-title":"J Neurooncol."},{"issue":"4","key":"2020101413244156400_CIT0006","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1111\/exd.12115","article-title":"NF1 gene silencing induces upregulation of vascular endothelial growth factor expression in both Schwann and non-Schwann cells","volume":"22","author":"Kawachi","year":"2013","journal-title":"Exp Dermatol."},{"issue":"30","key":"2020101413244156400_CIT0007","doi-asserted-by":"crossref","first-page":"4806","DOI":"10.1200\/JCO.2007.11.4017","article-title":"Phase I study of everolimus in pediatric patients with refractory solid tumors","volume":"25","author":"Fouladi","year":"2007","journal-title":"J Clin Oncol."},{"issue":"5","key":"2020101413244156400_CIT0008","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1158\/0008-5472.CAN-07-5916","article-title":"Preclinical cancer therapy in a mouse model of neurofibromatosis-1 optic glioma","volume":"68","author":"Hegedus","year":"2008","journal-title":"Cancer Res."},{"key":"2020101413244156400_CIT0009","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1146\/annurev.pharmtox.48.113006.094708","article-title":"Mechanism-based concepts of size and maturity in pharmacokinetics","volume":"48","author":"Anderson","year":"2008","journal-title":"Annu Rev Pharmacol Toxicol."},{"issue":"10","key":"2020101413244156400_CIT0010","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1200\/JCO.2007.14.5482","article-title":"Dose- and schedule-dependent inhibition of the mammalian target of rapamycin pathway with everolimus: a phase I tumor pharmacodynamic study in patients with advanced solid tumors","volume":"26","author":"Tabernero","year":"2008","journal-title":"J Clin Oncol."},{"issue":"19","key":"2020101413244156400_CIT0011","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1056\/NEJMoa1001671","article-title":"Everolimus for subependymal giant-cell astrocytomas in tuberous sclerosis","volume":"363","author":"Krueger","year":"2010","journal-title":"N Engl J Med."},{"issue":"4","key":"2020101413244156400_CIT0012","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1093\/neuonc\/nos330","article-title":"A multi-disciplinary consensus statement concerning surgical approaches to low-grade, high-grade astrocytomas and diffuse intrinsic pontine gliomas in childhood (CPN Paris 2011) using the Delphi method","volume":"15","author":"Walker","year":"2013","journal-title":"Neuro Oncol"},{"issue":"2","key":"2020101413244156400_CIT0013","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1002\/ijc.29711","article-title":"Single agent carboplatin for pediatric low-grade glioma: a retrospective analysis shows equivalent efficacy to multiagent chemotherapy","volume":"138","author":"Dodgshun","year":"2016","journal-title":"Int J Cancer."},{"issue":"10","key":"2020101413244156400_CIT0014","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1007\/s003810050539","article-title":"Chemotherapy for low-grade gliomas","volume":"15","author":"Reddy","year":"1999","journal-title":"Childs Nerv Syst."},{"issue":"12","key":"2020101413244156400_CIT0015","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.1016\/S0959-8049(98)00307-4","article-title":"Gliomas","volume":"34","author":"Cokgor","year":"1998","journal-title":"Eur J Cancer"},{"issue":"12","key":"2020101413244156400_CIT0016","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1200\/JCO.2011.34.5843","article-title":"Phase II study of weekly vinblastine in recurrent or refractory pediatric low-grade glioma","volume":"30","author":"Bouffet","year":"2012","journal-title":"J Clin Oncol."},{"issue":"29","key":"2020101413244156400_CIT0017","doi-asserted-by":"crossref","first-page":"3537","DOI":"10.1200\/JCO.2016.68.1585","article-title":"Phase II weekly vinblastine for chemotherapy-na\u00efve children with progressive low-grade glioma: a Canadian Pediatric Brain Tumor Consortium study","volume":"34","author":"Lassaletta","year":"2016","journal-title":"J Clin Oncol."},{"issue":"6","key":"2020101413244156400_CIT0018","first-page":"750","article-title":"Pediatric low-grade gliomas: implications of the biologic era","volume":"19","author":"Packer","year":"2017","journal-title":"Neuro Oncol."},{"issue":"2","key":"2020101413244156400_CIT0019","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1093\/neuonc\/not154","article-title":"Efficacy of bevacizumab plus irinotecan in children with recurrent low-grade gliomas\u2014a Pediatric Brain Tumor Consortium study","volume":"16","author":"Gururangan","year":"2014","journal-title":"Neuro Oncol."},{"issue":"4","key":"2020101413244156400_CIT0020","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1002\/pbc.24794","article-title":"A phase II trial of a multi-agent oral antiangiogenic (metronomic) regimen in children with recurrent or progressive cancer","volume":"61","author":"Robison","year":"2014","journal-title":"Pediatr Blood Cancer."},{"key":"2020101413244156400_CIT0021","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.critrevonc.2016.05.008","article-title":"Neurofibromatosis type 1 associated low grade gliomas: a comparison with sporadic low grade gliomas","volume":"104","author":"Helfferich","year":"2016","journal-title":"Crit Rev Oncol Hematol."},{"issue":"7","key":"2020101413244156400_CIT0022","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1016\/S1470-2045(19)30277-3","article-title":"Selumetinib in paediatric patients with BRAF-aberrant or neurofibromatosis type 1-associated recurrent, refractory, or progressive low-grade glioma: a multicentre, phase 2 trial","volume":"20","author":"Fangusaro","year":"2019","journal-title":"Lancet Oncol."},{"issue":"7","key":"2020101413244156400_CIT0023","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1002\/pbc.24958","article-title":"Long-term outcome of 4,040 children diagnosed with pediatric low-grade gliomas: an analysis of the Surveillance Epidemiology and End Results (SEER) database","volume":"61","author":"Bandopadhayay","year":"2014","journal-title":"Pediatr Blood Cancer."},{"issue":"6","key":"2020101413244156400_CIT0024","doi-asserted-by":"crossref","first-page":"e0158476","DOI":"10.1371\/journal.pone.0158476","article-title":"Long-term use of everolimus in patients with tuberous sclerosis complex: final results from the EXIST-1 study","volume":"11","author":"Franz","year":"2016","journal-title":"PLoS One."},{"issue":"12","key":"2020101413244156400_CIT0025","doi-asserted-by":"crossref","first-page":"2636","DOI":"10.1002\/cncr.21091","article-title":"Weekly vinblastine in pediatric low-grade glioma patients with carboplatin allergic reaction","volume":"103","author":"Lafay-Cousin","year":"2005","journal-title":"Cancer."},{"issue":"7","key":"2020101413244156400_CIT0026","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1056\/NEJMoa1904059","article-title":"Five-year outcomes with dabrafenib plus trametinib in metastatic melanoma","volume":"381","author":"Robert","year":"2019","journal-title":"N Engl J Med."}],"container-title":["Neuro-Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/neuro-oncology\/advance-article-pdf\/doi\/10.1093\/neuonc\/noaa071\/33322622\/noaa071.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/neuro-oncology\/article-pdf\/22\/10\/1527\/33884341\/noaa071.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/neuro-oncology\/article-pdf\/22\/10\/1527\/33884341\/noaa071.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,14]],"date-time":"2020-10-14T14:24:15Z","timestamp":1602685455000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/neuro-oncology\/article\/22\/10\/1527\/5814308"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,1]]},"references-count":26,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2020,4,1]]},"published-print":{"date-parts":[[2020,10,14]]}},"URL":"https:\/\/doi.org\/10.1093\/neuonc\/noaa071","relation":{},"ISSN":["1522-8517","1523-5866"],"issn-type":[{"value":"1522-8517","type":"print"},{"value":"1523-5866","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,10]]},"published":{"date-parts":[[2020,4,1]]}}}